William Blair Reiterates Outperform Rating for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “outperform” rating reissued by investment analysts at William Blair in a research report issued on Friday,RTT News reports. William Blair also issued estimates for Dynavax Technologies’ Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.28 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.61 EPS.

A number of other research firms have also weighed in on DVAX. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock opened at $13.33 on Friday. The stock has a market cap of $1.75 billion, a P/E ratio of 74.06 and a beta of 1.32. The stock’s 50 day simple moving average is $12.82 and its 200-day simple moving average is $12.03. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $14.05. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. The firm had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Analysts predict that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Dynavax Technologies

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in Dynavax Technologies in the 4th quarter valued at approximately $990,000. Assenagon Asset Management S.A. purchased a new stake in Dynavax Technologies in the 3rd quarter valued at approximately $8,291,000. Entropy Technologies LP purchased a new stake in Dynavax Technologies in the 3rd quarter valued at approximately $462,000. Nordea Investment Management AB boosted its holdings in Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after purchasing an additional 232,690 shares in the last quarter. Finally, Bank of Montreal Can boosted its holdings in Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock valued at $11,848,000 after purchasing an additional 82,449 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.